Measurement properties of the minimal disease activity criteria for psoriatic arthritis

被引:15
|
作者
Coates, Laura C. [1 ]
Strand, Vibeke [2 ]
Wilson, Hilary [3 ]
Revicki, Dennis [4 ]
Stolshek, Brad [5 ]
Samad, Ahmed [6 ]
Chung, James B. [7 ]
Gladman, Dafna [8 ]
Mease, Philip J. [9 ,10 ]
机构
[1] Univ Oxford, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Oxford, England
[2] Stanford Univ, Immunol Rheumatol, Stanford, CA 94305 USA
[3] Boehringer Ingelheim GmbH & Co KG, Ridgefield, CT 06877 USA
[4] Evidera Inc, Bethesda, MD USA
[5] Amgen Inc, Thousand Oaks, CA USA
[6] Pharmaceut Prod Dev, San Diego, CA USA
[7] Amgen Inc, Thousand Oaks, CA USA
[8] Krembil Res Inst, Med Rheumatol, Toronto, ON, Canada
[9] Swedish Med Ctr, Sch Med, Seattle, WA USA
[10] Univ Washington, Seattle, WA 98195 USA
来源
RMD OPEN | 2019年 / 5卷 / 02期
关键词
INADEQUATE RESPONSE; CLINICAL-PRACTICE; OUTCOME MEASURE; ACTIVITY STATES; DOUBLE-BLIND; RECOMMENDATIONS; REMISSION; PLACEBO; EPIDEMIOLOGY; TOFACITINIB;
D O I
10.1136/rmdopen-2019-001002
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective To comprehensively assess evidence on the measurement properties of the minimal disease activity (MDA) criteria, a composite measure of the state of disease activity in psoriatic arthritis (PsA). Methods A targeted literature review was conducted to identify studies that informed the validity and/or ability of the MDA to detect change among patients known to have experienced a change in clinical status. The search was conducted using MEDLINE and Embase databases (published as of October 2017). Pertinent articles provided by investigators and identified from select conference proceedings were also evaluated. Results A total of 20 publications met the inclusion criteria. The MDA criteria were consistently associated with other indicators of disease activity/severity. The ability of the MDA criteria to detect change was supported in randomised controlled trials (n=10), with a greater percentage of patients randomised to active treatments achieving MDA relative to patients in comparator arms. Long-term observational studies (n=2) provided additional support for the ability of the MDA to detect within-subject change in the real-world settings. Conclusion Evidence supports the MDA as a valid measure of disease activity in PsA that can detect between-group and within-subject change. The MDA is a comprehensive measure and clinically meaningful endpoint to assess the impact of interventions on PsA disease activity.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] Value and Prediction of Minimal Disease Activity in Patients with Psoriatic Arthritis.
    Kavanaugh, Arthur
    Mease, Philip
    Coates, Laura C.
    McInnes, Iain B.
    Hojnik, Maja
    Dorr, Alex
    Zhang, Ying
    Guerette, Benoit
    Friedman, Alan
    Gladman, Dafna D.
    [J]. ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S697 - S697
  • [32] Treatment response in psoriatic arthritis: a comparison between the disease activity scores psoriatic arthritis response criteria and disease activity score-28
    Patel, Khadijah
    Nair, Nisha
    Jani, Meghna
    Chinoy, Hector
    Bluett, James
    Barton, Anne
    Curry, Philippa
    [J]. RHEUMATOLOGY, 2024, 63
  • [33] Minimal Disease Activity among Psoriatic Arthritis Patients in Canada: Which Unmet Criteria are more Prevalent among Responders?
    Avina-Zubieta, Antonio
    Chow, Andrew
    Baer, Philip
    Kelsall, John
    Rahman, Proton
    Stewart, Jaqueline
    Haraoui, Boulos
    Zummer, Michel
    Rampakakis, Emmanouil
    Psaradellis, Eliofotisti
    Nantel, Francois
    Maslova, Karina
    Tkaczyk, Cathy
    Osborne, Brendan
    Lehman, Allen
    [J]. JOURNAL OF RHEUMATOLOGY, 2016, 43 (06) : 1174 - 1175
  • [34] Minimal Disease Activity Among Psoriatic Arthritis Patients in Canada: Which Unmet Criteria Are More Prevalent Among Responders?
    Avina-Zubieta, J. Antonio
    Chow, Andrew
    Baer, Philip
    Kelsall, John
    Rahman, Proton
    Stewart, Jacqueline
    Haraoui, Boulos
    Zummer, Michel
    Rampakakis, Emmanouil
    Psaradellis, Eliofotisti
    Nantel, Francois
    Maslova, Karina
    Tkaczyk, Cathy
    Osborne, Brendan
    Lehman, Allen J.
    [J]. ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [35] Remission criteria and activity indices in psoriatic arthritis
    M. L. Acosta Felquer
    L. Ferreyra Garrott
    J. Marin
    E. Catay
    M. Scolnik
    V. Scaglioni
    S. Ruta
    J. Rosa
    E. R. Soriano
    [J]. Clinical Rheumatology, 2014, 33 : 1323 - 1330
  • [36] Remission criteria and activity indices in psoriatic arthritis
    Acosta Felquer, M. L.
    Ferreyra Garrott, L.
    Marin, J.
    Catay, E.
    Scolnik, M.
    Scaglioni, V.
    Ruta, S.
    Rosa, J.
    Soriano, E. R.
    [J]. CLINICAL RHEUMATOLOGY, 2014, 33 (09) : 1323 - 1330
  • [37] DOES "MINIMAL DISEASE ACTIVITY" CORRELATES WITH COMPOSITE INDICES IN PATIENTS WITH PSORIATIC ARTHRITIS?
    Stolfa, J.
    Sedova, L.
    Mares, Z.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 968 - 968
  • [38] Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment
    Coates, L. C.
    Fransen, J.
    Helliwell, P. S.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2010, 69 (01) : 48 - 53
  • [39] DEFINITION OF REMISSION AND MINIMAL DISEASE ACTIVITY IN PSORIATIC ARTHRITIS: A SYSTEMATIC LITERATURE REVIEW
    Gudu, T.
    Ionescu, R.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 767 - 767
  • [40] The prediction and benefits of minimal disease activity in patients with psoriatic arthritis in ADEPT trial
    Mease, Philip
    Kavanaugh, Arthur
    Coates, Laura C.
    McInnes, Iain
    Hojnik, Maja
    Zhang, Ying
    Anderson, Jaclyn
    Dorr, Alexander
    Gladman, Dafna
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S13 - S13